Clopidogrel is a prescription antiplatelet medication used to reduce the formation of harmful blood clots in people at increased risk of cardiovascular events. It belongs to the P2Y12 platelet inhibitor class and is commonly used following certain heart attacks or strokes, in acute coronary syndrome, and in patients with established peripheral arterial disease.
Clopidogrel itself is a prodrug, meaning it must first be converted in the liver into an active metabolite. This process involves several cytochrome P450 enzymes, with CYP2C19 playing an especially important role. Once activated, the metabolite irreversibly binds to P2Y12 ADP receptors on platelets, preventing ADP mediated activation of the glycoprotein GPIIb/IIIa complex and reducing platelet aggregation.
Because this platelet inhibition is irreversible, platelets exposed to the active metabolite remain affected for the remainder of their normal lifespan, approximately 7–10 days. New platelets must therefore be produced before normal platelet function is fully restored after treatment is discontinued.
Clopidogrel is used in cardiovascular medicine to reduce the risk of myocardial infarction (heart attack) and ischemic stroke in appropriately selected patients. Established indications include acute coronary syndrome, recent myocardial infarction, recent ischemic stroke, and peripheral arterial disease. Depending on the cardiovascular condition, clopidogrel may also be prescribed alongside aspirin as part of dual antiplatelet therapy.
This product provides:
- Active Ingredient: Clopidogrel
- Form: Clopidogrel Bisulfate
- Strength: 75mg per tablet
- Quantity: 30 Tablets
- Drug Class: P2Y12 Antiplatelet Agent
- Dosage Form: Oral Tablet
- Common Uses: Prevention of heart attack, ischemic stroke and other cardiovascular clotting events
Health Canada’s Drug Product Database lists clopidogrel 75mg tablets as prescription medication in Canada, with multiple clopidogrel bisulfate formulations registered in tablet form.
One of the most important safety considerations associated with clopidogrel is bleeding. Because it reduces platelet aggregation, patients may bruise or bleed more easily, and serious bleeding can occur in some circumstances. Additional caution is required when clopidogrel is combined with anticoagulants, other antiplatelet medications, NSAIDs or other drugs that can increase bleeding risk.
The effectiveness of clopidogrel can also vary between individuals because activation depends significantly on CYP2C19 metabolism. People with genetic variants that substantially reduce CYP2C19 activity may generate less of the active metabolite and consequently receive less antiplatelet effect.
Certain medications can also interfere with CYP2C19 activity and reduce clopidogrel activation. Medication interactions should therefore be reviewed by a healthcare professional before treatment or when additional medications are introduced.
Patients taking clopidogrel should inform physicians, dentists, and other healthcare professionals before surgery or dental procedures, since its antiplatelet activity can affect bleeding. Clopidogrel should not be stopped without medical guidance, particularly when it has been prescribed following a cardiovascular event or coronary intervention.
Clopidogrel 75mg is a prescription medication and should be used according to the directions and monitoring recommendations of a qualified healthcare professional.
